Fresenius Kabi: Adalimumab Customers Want Supply Guarantee, We Can Provide That
Interchangeability ‘More Of A Legal Connotation,’ Firm Tells Generics Bulletin
Executive Summary
Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.
You may also be interested in...
Humira In 2023: The $17bn Biosimilar Opportunity
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.
Lannett Eyes Another $11M In Savings With R&D Sea Change, Job Cuts
Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.